renal cell carcinoma

The Secret Sauce Behind Exelixis, Inc.'s 12% Move Higher in December
The Secret Sauce Behind Exelixis, Inc.'s 12% Move Higher in December
Motley Fool
Exelixis
Cabometyx
renal cell carcinoma
Flag link:
Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
Yahoo/Zacks.com
Pfizer
Bavencio
immuno-oncology
renal cell carcinoma
lung cancer
ovarian cancer
head and neck cancer
Flag link:
Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx
Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx
Yahoo/Zacks.com
Exelixis
Bristol-Myers Squibb
clinical trials
Opdivo
Opdivo-Cabometyx
renal cell carcinoma
Flag link:
Here's Why AVEO Oncology Fell as Much as 12.7% Today
Here's Why AVEO Oncology Fell as Much as 12.7% Today
Motley Fool
Aveo Oncology
tivozanib
renal cell carcinoma
Flag link:
EMA Recommends New HCV, Cancer and MS Drugs for Approval
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Europe
EMA
hepatitis C
multiple sclerosis
breast cancer
renal cell carcinoma
AbbVie
Maviret
Gilead Sciences
Vosevi
Biogen
Amgen
Samsung Bioepis
biosimilars
Humira
Novartis
Kisqali
EUSA
Fotivda
Flag link:
Phase II Fail Prompts Acceleron to Discontinue Development of Renal Cell Carcinoma Drug
Phase II Fail Prompts Acceleron to Discontinue Development of Renal Cell Carcinoma Drug
Xtalks
Acceleron
renal cell carcinoma
clinical trials
Axitinib
Flag link:
Argos’ PhIII for its personalized cancer vaccine implodes during an interim analysis
Argos’ PhIII for its personalized cancer vaccine implodes during an interim analysis
Endpoints
Argos
personalized medicine
vaccines
rocapuldencel-T
renal cell carcinoma
Flag link:
5 Reasons Exelixis's Cabometyx Is Set To Be The Next Blockbuster Opportunity
5 Reasons Exelixis's Cabometyx Is Set To Be The Next Blockbuster Opportunity
Seeking Alpha
Exelixis
Cabometyx
renal cell carcinoma
Flag link:
These 3 Little Biotechs Just Scored Big
These 3 Little Biotechs Just Scored Big
Motley Fool
biotech
Celldex Therapeutics
melanoma
glemba
Exelixis
Cabometyx
renal cell carcinoma
Tesaro
ovarian cancer
niraparib
Flag link:
AVEO Collaborates With Bristol-Myers Squibb for RCC Drug
AVEO Collaborates With Bristol-Myers Squibb for RCC Drug
Investopedia
Aveo Pharmaceuticals
Bristol-Myers Squibb
renal cell carcinoma
tivozanib
Flag link:
Exelixis, Inc. Gets Some ASCO Love
Exelixis, Inc. Gets Some ASCO Love
Motley Fool
Exelixis
ASCO 2016
Cabometyx
renal cell carcinoma
Flag link:
Exelixis Rises on Positive Late-Stage Trial Results
Exelixis Rises on Positive Late-Stage Trial Results
24/7 Wall St
Exelixis
cabozantinib
renal cell carcinoma
clinical trials
Flag link:
FDA Grants Breakthrough Therapy Designation to Exelixis’ Cabozantinib for the Treatment of Renal Cell Carcinoma in Patients Who Received One Prior Therapy
FDA Grants Breakthrough Therapy Designation to Exelixis’ Cabozantinib for the Treatment of Renal Cell Carcinoma in Patients Who Received One Prior Therapy
Yahoo
FDA
Exelixis
breakthrough therapies
renal cell carcinoma
cabozantinib
Flag link:
Tivozanib Is the Gift That Keeps On Giving For Aveo
Tivozanib Is the Gift That Keeps On Giving For Aveo
24/7 Wall St
tivozanib
Aveo Oncology
renal cell carcinoma
Flag link:
IPO Preview: Argos Therapeutics
IPO Preview: Argos Therapeutics
Seeking Alpha
IPOs
Argos Therapeutics
AGS-003
renal cell carcinoma
Flag link:
Argos swings for a $60M IPO in the shadow of Dendreon's struggles
Argos swings for a $60M IPO in the shadow of Dendreon's struggles
Fierce Biotech
Argos
IPOs
Dendreon
AGS-003
personalized medicine
renal cell carcinoma
Flag link:
Merck and GlaxoSmithKline partner to evaluate renal cell carcinoma regimen
Merck and GlaxoSmithKline partner to evaluate renal cell carcinoma regimen
The Fly on the Wall
renal cell carcinoma
Merck
GSK
MK-3475
pazopanib
Flag link:
Threshold Pharmaceuticals Announces Data From Two Ongoing Phase 1/2 Trials of TH-302 at the 2013 ASCO Annual Meeting
Threshold Pharmaceuticals Announces Data From Two Ongoing Phase 1/2 Trials of TH-302 at the 2013 ASCO Annual Meeting
Yahoo/MarketWire
Threshold Pharmaceuticals
TH-302
Multiple Myeloma
gastrointestinal stromal tumors
renal cell carcinoma
kidney cancer
Flag link:
Lpath Initiates Dosing in First Proof-of-Concept Trial of Anti-Cancer Drug, ASONEP
Lpath Initiates Dosing in First Proof-of-Concept Trial of Anti-Cancer Drug, ASONEP
Yahoo
Lpath
Asonep
renal cell carcinoma
Flag link:
Bristol-Myers Has The Future Of Oncology Therapies
Bristol-Myers Has The Future Of Oncology Therapies
Seeking Alpha
Bristol-Myers Squibb
nivolumab
BMS-936558
non-small cell lung cancer
renal cell carcinoma
melanoma
Ono Pharmaceutical
tivozanib
Aveo Pharmaceuticals
elotuzumab
Flag link:

Pages